Mastercard Inc (MA) Stock News

A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements about its business operations. The lawsuit claims ADMA engaged in undisclosed related party transactions, used channel stuffing to inflate revenues, and lacked adequate internal controls. Following a short report by Culper Research on March 24, 2026, ADMA's stock fell 16.63%. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 can join the lawsuit.

A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) for the period between August 9, 2024 and March 25, 2026. The complaint alleges material misstatements regarding revenues, undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. The stock dropped 29.1% following a Culper Research report exposing these practices on March 24, 2026.

A class action securities lawsuit has been filed against ADMA Biologics, Inc. for allegedly failing to disclose material information and making false statements. The complaint alleges undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. Investors who purchased securities between August 9, 2024 and March 25, 2026 may be eligible to participate, with an August 10, 2026 deadline to request lead plaintiff status.

Delivered strong Q1 2026 comparable store sales growth 1 of 22.6% and total revenue growth of 37.0% Achieved a four-year high gross margin 1 of 67.4 %, an increase of 530 bps Expanded adjusted EBITDA margin 1 to 36.8 %, underscoring our luxury-inspired business model Continued successful expansion with new stores outperforming expectations Raised adjusted EBITDA margin guidance for Fiscal 2026 to 38.25%–39.50 % MONTRÉAL , June 16, 2026 /CNW/ - Groupe Dynamite Inc. ("Groupe Dynamite" or the "Company") (TSX: GRGD ) today reported its financial results for the fiscal year 2026's first quarter ended May 2, 2026. "Our first quarter results demonstrate the strength of our operating model and our ability to deliver profitable growth. Comparable store sales increased 22.6%, gross margin reached a four-year high, and adjusted EBITDA margin expanded to 36.8% of revenue, positioning ourselves alongside the world's most profitable fashion houses. We continue to strive to remain a highly productive specialty retailer with strong brands, exceptional unit economics, disciplined inventory management, attractive returns on capital, and a growth engine we have built over decades that continues to scale profitably," said Andrew Lutfy, Chief Executive Officer and Chair of the Board. "Q1 was a strong start to fiscal 2026. Across both GARAGE and DYNAMITE, customers responded positively to our assortments, marketing campaigns and the consistency of the experience we deliver across channels. Our real estate strategy continues to be a significant driver of growth, customer acquisition and profitability. By opening new locations in premium centers, optimizing our fleet and delivering a compelling in-store experience, we continue to drive significant productivity improvements across our store network. Most importantly, we continue to see strong customer engagement across both brands, reflected

Robbins LLP announced a class action lawsuit against ADMA Biologics for allegedly misleading investors regarding business operations. The complaint alleges undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. Following a March 24, 2026 Culper Research report exposing these issues, ADMA stock fell 16.6% on March 24 and an additional 15.0% on March 25, 2026.

A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. following allegations by Culper Research of channel stuffing, undisclosed related party transactions, and inflated revenue growth. The stock fell 29.1% on March 24-25, 2026, after the report alleged the company induced distributors to stock excess inventory using rebates and extended payment terms to artificially boost reported revenues. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 have until August 10, 2026 to file a lead plaintiff motion.

A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud involving undisclosed related party transactions, channel stuffing, and inadequate internal controls. The lawsuit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026, with a lead plaintiff deadline of August 10, 2026.

The S&P 500 experienced a 4.5% pullback from its May 27 record high of 7,621 to 7,248 (the 50-day moving average), which the author characterizes as a healthy bull market correction rather than the start of a bear market. The bounce back to 7,431.46 on broad participation and positive money flows suggests the uptrend remains intact. However, the author warns of underlying risks including record margin debt ($1.30 trillion), declining retail demand, and inverted equity risk premium as 10-year Treasuries now yield more than S&P 500 earnings. The portfolio remains at 100% equity exposure based on positive money flow signals, but disciplined risk management is maintained ahead of historically weak summer months and midterm election volatility.

Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH). The firm is seeking shareholders to join the investigation and has provided contact information for interested parties.

Hamanasi Adventure & Dive Resort in Belize has been recognized as the #1 hotel in Central America and #15 best hotel globally in the 2026 TripAdvisor Travelers' Choice Best of the Best Awards. The luxury boutique resort, which employs over 180 Belizean staff, was recognized for exceptional service and guest experiences. The award is given to fewer than 1% of TripAdvisor's 8 million listings.

XOMA Royalty Corporation announced quarterly preferred stock dividends for Series A and Series B preferred shareholders, with Series A receiving $0.53906 per share and Series B receiving $0.52344 per depositary share, payable on July 15, 2026. The company also announced the redemption of all outstanding preferred stock at $25.00 per share on July 14, 2026, in connection with its pending merger with Ligand Pharmaceuticals through Flex Merger Sub, Inc. Additionally, the record date for CVR distribution to common stockholders has been set for July 13, 2026.

A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. for the Class Period between August 9, 2024 and March 25, 2026. Culper Research alleged the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenues. The stock fell 29.1% over two trading days to $9.63 per share following the allegations. Investors have until August 10, 2026 to file a lead plaintiff motion.

A class action lawsuit has been filed against ADMA Biologics, Inc. for alleged securities fraud. Culper Research published a report accusing the company of channel stuffing, undisclosed related party transactions, and inflating revenue growth. The stock fell 29.1% over two trading days following the allegations. Shareholders who purchased ADMA securities between August 9, 2024 and March 25, 2026 can file claims by August 10, 2026.

Heinz and Heineken have announced their first official brand collaboration, launching a limited edition six-pack containing five Heineken beers and one bottle of Heinz Tomato Ketchup. The partnership also includes a limited edition jersey and a DIY six-pack option. The collaboration celebrates a 150-year connection between the two brands and includes a giveaway via Heinz's Instagram.

A securities class action lawsuit has been filed against ADMA Biologics, Inc. for the period between August 9, 2024 and March 25, 2026. The complaint alleges the company engaged in undisclosed related party transactions, used channel stuffing to inflate revenue, and lacked adequate internal controls. Following a critical report by Culper Research on March 24, 2026, ADMA stock fell 16.6% and an additional 15% the next day.

A class action lawsuit has been filed against ADMA Biologics, Inc. for alleged securities fraud. According to a Culper Research report, the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth in 2025. The stock fell 29.1% following the allegations. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 can participate in the lawsuit, with a deadline of August 10, 2026 to file a lead plaintiff motion.

Johnson & Johnson announced that IMAAVY (nipocalimab-aahu) achieved its primary endpoint in the Phase 2/3 ENERGY study for warm autoimmune hemolytic anemia (wAIHA). Patients receiving the 30 mg/kg dose were three times more likely to achieve durable hemoglobin improvements compared to placebo over 24 weeks. The drug demonstrated rapid onset of effect, early improvements in fatigue, and reduced steroid use, with a safety profile consistent with its approved indication in myasthenia gravis. The supplemental Biologics License Application has been granted FDA Priority Review.

Johnson & Johnson (NYSE: JNJ ) on Thursday presented detailed results from its Phase 2/3 ENERGY study showing that IMAAVY (nipocalimab-aahu) achieved a statistically significant, durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA). The rare blood disorder occurs when the immune system mistakenly produces IgG antibodies that attack and destroy healthy red blood cells at normal body temperatures . data-variant="card" data-news-mode="manual" > Read Also: Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 JNJ Drug Demonstrates Durable Hemoglobin Response The company said patients receiving the 30 mg/kg dose experienced a rapid onset of effect and were about three times more likely to achieve durable hemoglobin improvements than those receiving a placebo over 24 weeks . The randomized, placebo-controlled trial ... Full story available on Benzinga.com

MONTREAL , June 11, 2026 /CNW/ - Dollarama Inc. (TSX: DOL ) ("Dollarama" or the "Corporation") today reported its financial results for the first quarter ended May 3, 2026. Refer to "Selected Segmented Financial Information" on page 6 of this press release for additional information regarding the Corporation's Canadian and Australian reportable segments. Fiscal 2027 First Quarter Results Highlights Compared to Fiscal 2026 First Quarter Sales increased by 21.4% to $1,846.1 million, compared to $1,521.2 million Comparable store sales (1) in Canada increased by 5.6%, compared to 4.9% in the first quarter of the previous year EBITDA (1) increased by 17.4% to $582.5 million, representing an EBITDA margin (1) of 31.6%, compared to 32.6% Operating income increased by 11.2% to $432.2 million, representing an operating margin (1) of 23.4%, compared to 25.6% Net earnings increased by 10.4% to $302.3 million, resulting in a 13.3% increase in diluted net earnings per common share to $1.11, compared to $0.98 Unrealized gain of $16.4 million relating to the derivative on our equity-accounted investments, positively impacting EBITDA margin by 90 basis points and diluted net earnings per common share by $0.06 28 net new stores opened in Canada, compared to 22 in the corresponding period of the previous year; 8 net new stores opened and 13 stores renovated in Australia, all operating under the legacy banner 1,962,010 common shares repurchased for cancellation for $339.1 million "We delivered a strong performance in the first quarter of fiscal 2027 as we pursue profitable growth in our core Canadian market, generating strong comparable store sales growth, expanding our store network and progressing our Western Canada logistics hub project. We are also advancing our priorities across our international growth platforms with discipline. In Latin America, Dollarcity had a solid start to th

Rosen Law Firm has filed a class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges that ADMA engaged in undisclosed related party transactions, channel stuffing, lacked adequate internal controls, and made materially false statements about its business operations. Investors have until August 10, 2026 to move the court to serve as lead plaintiff.

ADMA Biologics has been sued for securities fraud for allegedly misleading investors about revenue growth through a channel-stuffing scheme involving its ASCENIV product and failing to disclose a related-party distribution relationship. A Culper Research report revealed the growth was driven by excess inventory rather than genuine demand, causing the stock to plummet from $13.59 to $8.29 per share. Investors who purchased shares between August 9, 2024, and March 25, 2026, may be eligible to recover losses.

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Manhattan Associates, Inc. The firm is seeking shareholders who own MANH stock to join the investigation. Similar investigations are also being conducted for Helen of Troy Limited and TruBridge, Inc.

Wall Street has coined a new acronym, MANGOS (Meta, Anthropic, Nvidia, Google, OpenAI, and SpaceX), representing the next generation of dominant tech stocks focused on AI infrastructure and space commercialization. Three of the six companies are preparing for historic IPOs, with SpaceX targeting a $1.75 trillion valuation and OpenAI filing confidentially. The publicly traded members—Nvidia ($5.05T market cap), Alphabet ($4.37T), and Meta ($1.49T)—are already massive, with significant capital concentration expected if the private companies go public at anticipated valuations.

From FAANG to Mag7 to MANGOS, Wall Street loves its acronyms—each one a barometer of its era . First came FAANG — Meta Platforms, Inc. (NASDAQ: META ) (formerly Facebook), Apple Inc. (NASDAQ: AAPL ) , Amazon.com, Inc. (NASDAQ: AMZN ) , Netflix, Inc. (NASDAQ: NFLX ) and Alphabet Inc. (NASDAQ: GOOGL ) (NASDAQ: GOOG ) — a five-letter shorthand coined around 2013 to capture the dominant internet-era growth stocks . It embodied the streaming and social media boom. Then came the Magnificent Seven, which reflected the cloud and AI infrastructure buildout by swapping Netflix for Microsoft Corp. (NASDAQ: MSFT ) and Tesla, Inc. (NASDAQ: TSLA ) and added Nvidia Corp. (NASDAQ: NVDA ) . Now there’s MANGOS: Meta, Anthropic, Nvidia, Google (Alphabet), OpenAI and SpaceX — and this one breaks every rule that came before it. TSLA stock is moving. See the chart and price ... Full story available on Benzinga.com

Edward Smolyansky, largest shareholder and former COO of Lifeway Foods, criticizes the Board's governance, stating the poison pill was only terminated after ISS recommended voting against all directors. He highlights a pattern of reactive governance, the reversal of a board refresh process, and calls for shareholders to vote against incumbent directors at the June 17 Annual Meeting to register dissatisfaction with the Board's conduct.

Securities law firm BFA Law announced an investigation into RE/MAX Holdings' board of directors and co-founder David Liniger regarding potential breaches of fiduciary duties in connection with the pending merger with The Real Brokerage Inc. at $13.80 per share. The investigation examines whether the merger price is unfairly low and if insiders are receiving disproportionate benefits compared to public shareholders.

Tourmaline Oil Corp. announced a quarterly cash dividend of $0.50 per share payable on June 30, 2026, and held its annual shareholder meeting on June 3, 2026, where ten directors were elected. The company is Canada's largest natural gas producer focused on low-cost development in the Western Canadian Sedimentary Basin.

Sika has appointed Philipp Irniger as Head Construction and member of the executive board effective June 1, 2026, succeeding Ivo Schädler who retires after 30+ years. The company also created a new Chief Digital & Information Officer position, with Jochen Werling taking the role to accelerate digital transformation and the Fast-Forward program.

Sika has appointed Philipp Irniger as Head of Construction and Group Management member, effective June 1, 2026, succeeding Ivo Schädler who is retiring. Additionally, Sika created a new Chief Digital & Information Officer position to accelerate its digital transformation strategy and strengthen its digital leadership in the industry.